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Abstract
Background
Estimates of sexually transmitted infection (STI) prevalence are essential for efforts to pre-
vent and control STIs. Few large STI prevalence studies exist, especially for low- and mid-
dle-income countries (LMICs). Our primary objective was to estimate the prevalence of
chlamydia, gonorrhea, trichomoniasis, syphilis, herpes simplex virus type 2 (HSV-2), and
bacterial vaginosis (BV) among women in sub-Saharan Africa by age, region, and popula-
tion type.
Methods and findings
We analyzed individual-level data from 18 HIV prevention studies (cohort studies and ran-
domized controlled trials; conducted during 1993–2011), representing >37,000 women, that
tested participants for1 selected STIs or BV at baseline. We used a 2-stage meta-analysis
to combine data. After calculating the proportion of participants with each infection and stan-
dard error by study, we used a random-effects model to obtain a summary mean prevalence
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of each infection and 95% confidence interval (CI) across ages, regions, and population
types. Despite substantial study heterogeneity for some STIs/populations, several patterns
emerged. Across the three primary region/population groups (South Africa community-
based, Southern/Eastern Africa community-based, and Eastern Africa higher-risk), preva-
lence was higher among 15–24-year-old than 25–49-year-old women for all STIs except
HSV-2. In general, higher-risk populations had greater prevalence of gonorrhea and syphilis
than clinic/community-based populations. For chlamydia, prevalence among 15–24-year-
olds was 10.3% (95% CI: 7.4%, 14.1%; I2 = 75.7%) among women specifically recruited
from higher-risk settings for HIV in Eastern Africa and was 15.1% (95% CI: 12.7%, 17.8%;
I2 = 82.3%) in South African clinic/community-based populations. Among clinic/community-
based populations, prevalence was generally greater in South Africa than in Southern/East-
ern Africa for most STIs; for gonorrhea, prevalence among 15–24-year-olds was 4.6% (95%
CI: 3.3%, 6.4%; I2 = 82.8%) in South Africa and was 1.7% (95% CI: 1.2%, 2.6%; I2 = 55.2%)
in Southern/Eastern Africa. Across the three primary region/population groups, HSV-2 and
BV prevalence was high among 25–49-year-olds (ranging from 70% to 83% and 33% to
44%, respectively). The main study limitation is that the data are not from random samples
of the target populations.
Conclusions
Combining data from 18 HIV prevention studies, our findings highlight important features of
STI/BV epidemiology among sub-Saharan African women. This methodology can be used
where routine STI surveillance is limited and offers a new approach to obtaining critical infor-
mation on STI and BV prevalence in LMICs.
Author summary
Why was this study done?
• Sexually transmitted infections (STIs) and bacterial vaginosis (BV) can result in a range
of sexual, reproductive, and maternal-child health consequences.
• Few population-based studies of STI/BV prevalence exist for low- and middle-income
countries.
• Many HIV prevention studies gather baseline data on STIs, and, although not the pri-
mary objective of the studies, these data may be useful for estimating STI/BV
prevalence.
What did the researchers do and find?
• We used individual-level data from 18 HIV prevention studies conducted in sub-Saha-
ran Africa, which tested over 37,000 HIV-negative women for 1 or more STIs or BV at
baseline.
STIs/BV among women in Sub-Saharan Africa
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• Using a 2-stage meta-analysis, we estimated the prevalence of 5 STIs (chlamydia, gonor-
rhea, trichomoniasis, syphilis, and herpes simplex virus type 2 [HSV-2]) and BV across
studies by age, region, and population type.
• STI prevalence was highest among young women aged 15–24 years for all STIs except
HSV-2, regardless of region or population type.
• Estimated STI/BV prevalence often varied by region. For example, chlamydia and gon-
orrhea prevalence was higher among South African women enrolled from clinic/com-
munity settings than among similar populations elsewhere in Southern/Eastern Africa.
• Some STIs, such as syphilis, appeared to be primarily concentrated among higher-risk
populations.
What do these findings mean?
• Findings from this study strengthen our understanding of STI/BV epidemiology among
sub-Saharan African women.
• By identifying differences in STI/BV prevalence by age, region, and population type,
this analysis addresses the first pillar of the World Health Organization Global Health
Sector Strategy on Sexually Transmitted Infections 2016–2021: to increase information
for focused public health action.
• Existing data from research studies provide an opportunity to obtain critical informa-
tion on STI/BV prevalence and can be used where routine STI surveillance and stand-
alone STI studies are limited.
Introduction
Sexually transmitted infections (STIs) and bacterial vaginosis (BV) are widespread globally.
These conditions have important sexual, reproductive, and maternal-child health conse-
quences, including genital symptoms, pregnancy complications, infertility, enhanced HIV
transmission, and psychosocial effects. The World Health Organization (WHO) estimated
that, in 2012, there were 357 million new episodes of 4 curable STIs (chlamydia, gonorrhea,
syphilis, and trichomoniasis) [1] and 417 million people had infection with herpes simplex
virus type 2 (HSV-2) [2]. Global estimates of BV occurrence are limited [3].
The WHO Global Health Sector Strategy on Sexually Transmitted Infections 2016–2021
(Global Strategy), provides goals, targets, and priority actions for stemming the STI epidemic
[4]. As data on STI burden are critical for efforts to prevent, control, and manage STIs, the first
strategic direction of the Global Strategy is to increase information, including STI prevalence
estimates, for focused public health action. Estimating the global burden of STIs is hampered
by the limited availability of STI diagnostic testing and surveillance and a paucity of high-qual-
ity published studies of STI prevalence in low- and middle-income countries (LMICs), for
both general and key populations. Given these limitations, a WHO Consultation on Methods
for Improved Global STI Estimates highlighted the importance of exploring potential data
available through clinical research studies and trial networks to improve estimates [5], because
STIs/BV among women in Sub-Saharan Africa
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1002511 February 27, 2018 3 / 38
many studies gather baseline data on STIs, even when estimating STI prevalence is not a pri-
mary study objective.
In one collection of such studies, investigators used combined data from 18 prospective
HIV prevention studies in sub-Saharan Africa in an individual participant data (IPD) meta-
analysis to examine the association between hormonal contraceptive (HC) use and HIV acqui-
sition [6]. Although the main objective of these studies was not to estimate STI/BV prevalence,
all of them captured information on at least some STIs or BV. The 18 studies in the HC-HIV
IPD dataset include more than 37,000 women in 9 countries in sub-Saharan Africa [7–33] and
present a unique opportunity to explore prevalence of selected sexually transmitted and repro-
ductive tract infections.
In the current study, we used IPD meta-analysis to estimate the prevalence of selected STIs
and BV, and the prevalence of co-infections, among women in sub-Saharan Africa participat-
ing in these 18 studies. We selected STIs included in the majority of the studies (chlamydia,
gonorrhea, trichomoniasis, syphilis, and HSV-2), and present STI/BV prevalence by age,
region, and population type.
Methods
We followed a protocol and a prespecified analysis plan (S3 Text). We report our findings in
accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) (S1 Text) and provide a checklist of items specific to IPD meta-analyses (S2 Text).
PRISMA checklists for previous IPD analyses of these data are also available [6,34]. The US
Centers for Disease Control and Prevention, WHO, and the Protection of Human Subjects
Committee of FHI 360 determined that the research was exempt from ethical review. All
included studies had relevant country-specific institutional ethical review and regulatory
board approvals, and all participants within each study provided written informed consent for
study participation. All principal investigators agreed to share their data for the present meta-
analysis.
Study eligibility and inclusion criteria
The collection of studies included in the current analysis started as the Vaginal Practices
Research Partnership, in which investigators combined data from 10 cohort studies and HIV
prevention trials in sub-Saharan Africa in an IPD meta-analysis to examine associations of
women’s intravaginal practices and acquisition of HIV [34]. Data from 8 additional studies
were then added for the evaluation of the association between HC and HIV acquisition [6].
The final 18 studies in the HC-HIV IPD meta-analysis included HIV-negative women
recruited from general populations and groups of women identified to be at higher-risk of
HIV infection, such as women engaging in transactional sex. Women were not randomly sam-
pled. Initial inclusion and exclusion criteria for the IPD meta-analysis of HC and HIV acquisi-
tion are listed in S1 Table. In general, studies had to include women between the ages of 15
and 49 years, measure HIV prospectively at multiple time points, and measure HC use.
To minimize the risk of measurement bias, additional inclusion criteria for the current IPD
meta-analysis to estimate STI/BV prevalence were applied separately for chlamydia, gonor-
rhea, trichomoniasis, syphilis, HSV-2, and BV. To be included, the study had to have (1) mea-
sured the STI/BV at baseline as part of its protocol, (2) provided information about both the
diagnostic test and the test result, and (3) tested at least 80% of all participants in the study for
the STI/BV or tested at least 80% of a randomly selected sample of enrolled participants. Stud-
ies were excluded from prevalence estimation for a specific STI/BV if (1) the study design
required the STI/BV diagnosis in question for study inclusion (e.g., participants required to be
STIs/BV among women in Sub-Saharan Africa
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HSV-2 antibody positive) or (2)>10% of those tested for the STI/BV had indeterminate test
results.
Data collection, data management, and data items
The investigators of each eligible study gave us permission to use their data in the STI meta-
analysis. We included variables at both study and individual level. Study-level variables
included country, study design, population types, study aims, recruitment period, and diag-
nostic procedures. Individual-level variables included sociodemographic variables (age, educa-
tion, marital status, employment status, number of live births) and sexual behavior variables
(condom use at last sex, age at first sex, coital frequency, number of lifetime partners, new part-
ners, concurrent partners, and contraceptive use). The study team worked closely with the
data managers and investigators of the individual studies to clarify issues about variable defini-
tion and missing, incomplete, or implausible data.
Definition of prevalent STI or BV
Prevalent STI was defined, based on the baseline study visit, as a positive test result by prespec-
ified tests for each pathogen: Chlamydia trachomatis (chlamydia)—nucleic acid amplification
test (NAAT), enzyme immunoassay (EIA) test, or hybrid capture test; Neisseria gonorrhoeae
(gonorrhea)—NAAT or culture; Trichomonas vaginalis (trichomoniasis)—NAAT, InPouch
(BioMed Diagnostics, White City, OR) culture, or wet mount; HSV-2 infection—type-specific
serologic test; Treponema pallidum (syphilis)—any rapid plasma reagin (RPR) and a trepone-
mal test (Treponema pallidum hemagglutination assay [TPHA], Treponema pallidum particle
agglutination assay [TPPA], or Determine Rapid Syphilis TP Assay [Abbott Laboratories,
Tokyo, Japan]). A subset of studies recorded RPR titer, and for these studies, we defined high-
titer, active syphilis as an RPR titer 1:8 and a positive treponemal test [35]. Prevalent BV
diagnosis was based on Nugent score 7 or Ison-Hay grade grade III.
Stratification of prevalence estimates
We initially selected 5 factors likely to influence STI/BV prevalence for stratification: partici-
pant age, region, population type, time period, and pregnancy status. After preliminary exami-
nation of the available data, we stratified prevalence estimates only by participant age, region,
and study population type. We decided not to stratify studies by time period or pregnancy sta-
tus given limited sample size.
We categorized age as 15–24 years or 25–49 years, according to individual participant age
at the baseline visit. We defined 3 regions (based on geographical location of the study): South
Africa, Eastern Africa (Kenya, Uganda, Tanzania, Rwanda), and Southern Africa (Zambia,
Zimbabwe, Malawi, Botswana). Studies that were conducted in more than 1 region were split
into sub-studies that included only a single region. We defined 3 study population types
(based on enrollment and inclusion criteria for each study): clinic/community-based popula-
tions, higher-risk populations, and HIV-discordant couples. Clinics were family planning and
reproductive health clinics and enrolled women regardless of symptom status. Community-
based settings included enrollment at community meetings or house-to-house visits. Higher-
risk populations included studies where participants were recruited from bars or other recrea-
tional facilities like guesthouses and hotels that were considered high-risk venues for acquiring
HIV infection, or were recruited because they engaged in transactional sex. Studies of HIV-
discordant couples included the HIV-negative partners of HIV-discordant partnerships. Stud-
ies that included participants from multiple population types were split into multiple sub-stud-
ies for analysis.
STIs/BV among women in Sub-Saharan Africa
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Analysis
Descriptive analysis. Participant characteristics (sociodemographic characteristics, risk
behaviors, etc.) were compared across the strata of participant age, region, and population
type.
Prevalence estimation and meta-analysis. Using individual-level participant data, we
used 2-stage meta-analysis to derive summary estimates of the mean prevalence of each infec-
tion according to the prespecified strata of age group, region, and study population type. In
the first stage, we used the data from participants in each individual study to obtain the pro-
portion infected and standard error on the logit scale. Some strata contained 1 or more studies
with 0 infections, for which the logarithm is undefined. For all studies in these strata, we used
the observed proportion and estimated the standard error using the exact binomial confidence
limits. In the second stage, we used a random-effects model to pool the log odds of infection
across studies, weighted by the variability of the estimate of the individual studies. The pooled
log odds and 95% confidence interval (CI) were then transformed to obtain summary preva-
lence estimates on the natural scale. We generated forest plots in R and inspected them visually
to compare prevalence estimates across strata, and combined strata if estimates were similar.
We used the I2 statistic to describe the percentage of variability in prevalence estimates result-
ing from between-study heterogeneity rather than sampling error. We applied approximate
categories of I2 values to determine low heterogeneity (I2 < 50%), mild or moderate heteroge-
neity (I2 from 50% to 75%), and high heterogeneity (I2 > 75%) and used these categories in the
interpretation of summary estimates of prevalence [36].
Prevalence of co-infection. We investigated the prevalence of co-infection among
women tested for each combination of infections (e.g., tested for both HSV-2 and gonorrhea).
For each infection, we estimated the prevalence of co-infection with an additional infection
(e.g., among women with HSV-2, the prevalence of gonorrhea) among women tested for both
infections. Co-infection prevalence was estimated for each stratum using the methods
described above.
Results
All 18 potentially eligible studies included testing for at least 1 STI and/or BV testing at base-
line. Test technologies varied across studies (S2 Table). Five studies included multiple geo-
graphic regions and/or population types and were split into separate sub-studies for analysis,
resulting in a total of 26 studies/sub-studies (hereafter referred to as “studies”) (Table 1). There
were 10 studies in South Africa that were conducted among clinic/community-based popula-
tions (N = 9) and HIV-discordant couples (N = 1). Nine studies were conducted in Southern
Africa (N = 5) or Eastern Africa (N = 4) among clinic/community-based populations (N = 7)
and HIV-discordant couples (N = 2). Seven studies were conducted in Eastern Africa among
higher-risk populations. Sample sizes of included studies ranged from 138 to 5,654.
Prevalence estimates from studies of HIV-discordant couples were similar to those from
studies of clinic/community-based populations, so we combined these population types (sub-
sequently referred to as “clinic/community-based studies”). In addition, prevalence estimates
from clinic/community-based studies in Southern and Eastern Africa were similar, and these
groups were combined (subsequently referred to as “Southern/Eastern Africa”). Our main
results are presented by age group (15–24 and 25–49 years) for South African clinic/commu-
nity-based populations, Southern/Eastern African clinic/community-based populations, and
Eastern African higher-risk populations. Participant characteristics and STI/BV prevalence
estimates according to the initial stratification variables for age, region, and population type
are shown in S3 Table and S1–S8, S11–S18 Figs.
STIs/BV among women in Sub-Saharan Africa
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Table 1. Summary characteristics of included studies.
Study ID
[References]
Country Region Study population Population
type category
Study design; objective Study
period
Ages
included,
years
Median
age, years
N
included
S1 [7,8] Kenya Eastern
Africa
Women who engage in
transactional sex
Higher-risk Cohort; hormonal
contraception and HIV
1993–
2002
16–48 26 1,219
S2 [9,10] South Africa South
Africa
Women not screened
for cervical cancer
Clinic/
community-
based
RCT; cervical cancer
screening interventions
2000–
2002
35–49 40 4,158
S3a [11,12] Uganda Eastern
Africa
Women attending
reproductive health
clinics
Clinic/
community-
based
Cohort; hormonal
contraception and HIV
1999–
2002
18–35 24 2,194
S3b [11,12] Zimbabwe Southern
Africa
Women attending
reproductive health
clinics
Clinic/
community-
based
Cohort; hormonal
contraception and HIV
1999–
2002
18–35 26 2,231
S4 [13] Kenya Eastern
Africa
Women who engage in
transactional sex
Higher-risk RCT; presumptive
antibiotic treatment
1998–
2002
18–49 27 399
S5 [14] Tanzania Eastern
Africa
Women working in bars Higher-risk Cohort; microbicide
feasibility study
2002–
2003
15–49 28 930
S6 [15,16] Tanzania Eastern
Africa
Women working in bars
and other recreational
facilities
Higher-risk RCT; HSV suppression
to reduce HIV
transmission
2003–
2006
16–35 28 769
S7a [17,18] Zimbabwe Southern
Africa
Sexually active women Clinic/
community-
based
RCT; diaphragm/
condoms to reduce
HIV acquisition
2003–
2005
18–49 28 1,648
S7b [17,18] South Africa South
Africa
Sexually active women Clinic/
community-
based
RCT; diaphragm/
condoms to reduce
HIV acquisition
2003–
2005
18–49 27 2,426
S8 [19] South Africa South
Africa
Women attending
reproductive health
clinics
Clinic/
community-
based
Cohort; hormonal
contraception and HIV
1999–
2001
18–41 27 545
S9 [20] South Africa South
Africa
Women attending
clinics
Clinic/
community-
based
Cohort; microbicide
feasibility study
2002–
2004
18–35 23 690
S10 [21] South Africa South
Africa
Women attending
clinics
Clinic/
community-
based
Cohort; microbicide
feasibility study
2003–
2004
15–49 27 256
S11 [22,23] Malawi,
Zimbabwe
Southern
Africa
Women attending
clinics
Clinic/
community-
based
Cohort; microbicide
feasibility study
2001–
2002
18–49 26 1,423
S12 [24,25] South Africa South
Africa
Sexually active women Clinic/
community-
based
RCT; microbicide to
reduce HIV acquisition
2004–
2006
16–49 28 5,615
S13 [26] Uganda Eastern
Africa
Women who engage in
transactional sex
Higher-risk Cohort; microbicide
feasibility study
2008–
2009
15–49 26 418
S14 [27] Tanzania Eastern
Africa
Women working in
food and recreational
facilities
Higher-risk Cohort; microbicide
feasibility study
2008–
2009
18–44 27 873
S15a [28,29] Kenya, Uganda,
Rwanda,
Tanzania
Eastern
Africa
Sexually active women
whose partners had
HIV and HSV-2
HIV-
discordant
couples
RCT; HSV suppression
to reduce HIV
transmission
2004–
2009
18–49 29 913
S15b [28,29] Botswana,
Zambia
Southern
Africa
Sexually active women
whose partners had
HIV and HSV-2
HIV-
discordant
couples
RCT; HSV suppression
to reduce HIV
transmission
2004–
2009
18–49 31 214
S15c [28,29] South Africa South
Africa
Sexually active women
whose partners had
HIV and HSV-2
HIV-
discordant
couples
RCT; HSV suppression
to reduce HIV
transmission
2004–
2009
18–49 32 138
(Continued)
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Participant characteristics
Among 15–24-year-old participants, sociodemographics varied across the 3 region/population
types (Table 2). For example, among participants recruited from clinic/community settings,
participants in studies from South Africa were more likely to be unmarried (92.1%) compared
with participants in studies in Southern/Eastern Africa (14.3%). As expected, participants in
Eastern Africa higher-risk population studies were more likely to be sex workers and to report
2 or more recent sex partners compared with participants in clinic/community-based studies.
Among 25–49-year-old participants, there were similar differences in sociodemographics and
sexual behaviors across the 3 region/population types (Table 3).
Prevalence estimates
Chlamydia. Among women aged 15–24 years in clinic/community-based populations in
South Africa, estimated chlamydia prevalence ranged from 8.0% to 20.6% (summary estimate:
15.1% [95% CI: 12.7%, 17.8%]; I2 = 82.3%), which was similar to estimated prevalence in the
higher-risk populations in Eastern Africa, which ranged from 5.0% to 15.8% (summary esti-
mate: 10.3% [95% CI: 7.4%, 14.1%]; I2 = 75.7%) (Fig 1). Prevalence was lower in the clinic/
community-based populations in Southern/Eastern Africa, with a summary average estimate
of 2.7% (95% CI: 1.5%, 3.9%; I2 = 81.1%).
Summary estimates of chlamydia prevalence were lower among women aged 25–49 years
than among women aged 15–24 years in all region/population types (Fig 2). In the clinic/com-
munity-based populations in Southern/Eastern Africa, the summary estimate of prevalence
among 25–49-year-old women was 1.2% (95% CI: 0.8%, 1.7%; I2 = 61.7%). In the higher-risk
populations in Eastern Africa, the summary estimate of prevalence was 6.2% (95% CI: 4.7%,
8.2%; I2 = 73.4%).
Table 1. (Continued)
Study ID
[References]
Country Region Study population Population
type category
Study design; objective Study
period
Ages
included,
years
Median
age, years
N
included
S16a [30,31] Tanzania Eastern
Africa
Women working in bars
and other recreational
facilities
Higher-risk RCT; microbicide to
reduce HIV acquisition
2005–
2008
16–49 29 1,018
S16b [30,31] Uganda Eastern
Africa
Women in HIV-
discordant partnerships
HIV-
discordant
couples
RCT; microbicide to
reduce HIV acquisition
2005–
2008
16–49 31 774
S16c [30,31] Zambia Southern
Africa
Sexually active women Clinic/
community-
based
RCT; microbicide to
reduce HIV acquisition
2005–
2008
18–49 27 1,150
S16d [30,31] South Africa South
Africa
Sexually active women Clinic/
community-
based
RCT; microbicide to
reduce HIV acquisition
2005–
2008
17–49 26 5,654
S17 [32] South Africa South
Africa
Sexually active women Clinic/
community-
based
RCT; microbicide to
reduce HIV acquisition
2007–
2009
18–40 22 444
S18a [33] Kenya,
Tanzania
Eastern
Africa
Sexually active women Clinic/
community-
based
RCT; microbicide to
reduce HIV acquisition
2009–
2011
18–35 26 380
S18b [33] South Africa South
Africa
Sexually active women Clinic/
community-
based
RCT; microbicide to
reduce HIV acquisition
2009–
2011
18–35 22 639
HSV, herpes simplex virus; HSV-2, herpes simplex virus type 2; RCT, randomized controlled trial.
https://doi.org/10.1371/journal.pmed.1002511.t001
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Table 2. Baseline characteristics by region/population type among participants aged 15–24 years.
Characteristic South African clinic/community
(N = 7,009)
Southern/Eastern African clinic/community
(N = 4,121)
Eastern African higher-risk
(N = 1,942)
Total (N =
13,072)
Sociodemographics
Age group
15–19 1,956 (27.9) 736 (17.9) 419 (21.6) 3,111 (23.8)
20–24 5,053 (72.1) 3,385 (82.1) 1,523 (78.4) 9,961 (76.2)
Total 7,009 (100) 4,121 (100) 1,942 (100) 13,072 (100)
Missing 0 0 0 0
Education
No school 41 (0.8) 122 (3.0) 137 (7.6) 300 (2.6)
Primary incomplete 110 (2.0) 588 (14.3) 421 (23.3) 1,119 (9.9)
Primary complete 123 (2.3) 715 (17.4) 825 (45.7) 1,663 (14.7)
Secondary incomplete 2,301 (42.4) 2,153 (52.2) 288 (16.0) 4,742 (41.8)
Secondary complete 2,554 (47.1) 358 (8.7) 81 (4.5) 2,993 (26.4)
Tertiary level 299 (5.5) 185 (4.5) 54 (3.0) 538 (4.7)
Total 5,428 (77.4) 4,121 (100) 1,806 (93.0) 11,355 (86.9)
Missing 1,581 0 136 1,717
Married/living with
partner
Yes 552 (7.9) 3,530 (85.7) 267 (13.8) 4,349 (33.3)
No 6,457 (92.1) 591 (14.3) 1,675 (86.3) 8,723 (66.7)
Total 7,009 (100) 4,121 (100) 1,942 (100) 13,072 (100)
Missing 0 0 0 0
Employed
Yes 653 (12.0) 1,139 (27.6) 1,801 (99.7) 3,593 (31.7)
No 4,770 (88.0) 2,982 (72.4) 6 (0.33) 7,758 (68.4)
Total 5,423 (77.4) 4,121 (100) 1,807 (93.1) 11,351 (86.8)
Missing 1,586 0 135 1,721
Number of live births 1 (0–1) 1 (1–2) 1 (0–2) 1 (0–1)
Sexual behaviors
Condom use at last sex
Yes 4,213 (67.8) 1,613 (46.6) 587 (48.0) 6,413 (58.9)
No 1,998 (32.2) 1,847 (53.4) 637 (52.0) 4,482 (41.1)
Total 6,211 (88.6) 3,460 (84.0) 1,224 (63.0) 10,895 (83.4)
Missing 798 661 718 2,177
Age at first sex 17 (17–17) 17 (16–18) 17 (15–17) 17 (16–18)
Coital frequency in past
month
8 (4–12) 12 (7–16) 4 (2–11) 8 (4–12)
Number of lifetime
partners
2 (1–3) 1 (1–3) 3 (3–8) 2 (1–3)
New partner
Yes 92 (3.1) 86 (2.9) 80 (82.5) 258 (4.3)
No 2,859 (96.9) 2,881 (97.1) 17 (17.5) 5,757 (95.7)
Total 2,951 (42.1) 2,967 (72) 97 (5.0) 6,015 (46.0)
Missing 4,058 1,154 1,845 7,057
Concurrent partner
Yes 260 (4.3) 162 (5.5) 172 (22.7) 594 (6.1)
No 5,736 (95.7) 2,777 (94.5) 587 (77.3) 9,100 (93.9)
Total 5,996 (85.6) 2,939 (71.3) 759 (39.1) 9,694 (74.2)
(Continued)
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Gonorrhea. For women aged 15–24 years in clinic/community-based populations in
South Africa, estimates of gonorrhea prevalence ranged from 1.4% to 8.9% in individual stud-
ies, and the summary estimate was 4.6% (95% CI: 3.3%, 6.4%; I2 = 82.8%) (Fig 3). The sum-
mary estimate of gonorrhea prevalence in clinic/community-based populations in Southern/
Eastern Africa was 1.7% (95% CI: 1.2%, 2.6%; I2 = 55.2%). In the higher-risk populations in
Eastern Africa, estimates in individual studies ranged from 5.2% to 15.2%, with a summary
estimate of 8.2% (95% CI: 5.8%, 11.6%; I2 = 80.7%). As for chlamydia, prevalence of gonorrhea
among women aged 25–49 years was generally lower than among women aged 15–24 years
across all strata, and heterogeneity in all strata was high (Fig 4).
Syphilis, overall (high, low, and unknown titer infection). Among 15–24-year-old
women, the summary estimate of syphilis prevalence overall (i.e., proportion of participants
with a positive RPR and positive treponemal test) was less than 2% in clinic/community popu-
lations in both South Africa (1.5% [95% CI: 1.0%, 2.2%]; I2 = 57.7%) and Southern/Eastern
Africa (1.4% [95% CI: 1.0%, 1.9%]; I2 = 25.8%), and higher among higher-risk populations in
Eastern Africa (8.4% [95% CI: 6.8%, 10.3%]; I2 = 46.3%) (Fig 5).
Among 25–49-year-olds in clinic/community populations in South Africa, the summary
estimate of syphilis prevalence overall among 25–49-year-old women (4.3% [95% CI: 2.5%,
7.2%]; I2 = 94.8%) was higher than that among younger women (1.5%) (Fig 6). In clinic/com-
munity populations in Southern/Eastern Africa, the summary estimate of syphilis prevalence
overall (2.0% [95% CI: 1.4%, 2.6%]; I2 = 61.8%) was similar to the summary estimate among
younger women (1.4%). In the higher-risk populations in Eastern Africa, the summary esti-
mate among older women (7.5% [95% CI: 5.5%, 10.1%]; I2 = 85.8%) was similar to prevalence
among younger women (8.4%).
Syphilis, high-titer infection. Among 15–24-year-olds, the prevalence of high-titer, active
infectious syphilis (i.e., participants with an RPR titer 1:8 and a positive treponemal test,
among those with RPR titers) mirrored that of overall syphilis, but with low or no between-
study heterogeneity (Fig 7). The summary estimate of prevalence in clinic/community popula-
tions in South Africa was 0.4% (95% CI: 0.3%, 0.5%; I2 = 0%) and in Southern/Eastern Africa
was 1.1% (95% CI: 0.3%, 1.9%; I2 = 42.5%). Among higher-risk populations in Eastern Africa,
the summary estimate was 4.5% (95% CI: 3.6%, 5.5%; I2 = 0%). Point estimates for women
Table 2. (Continued)
Characteristic South African clinic/community
(N = 7,009)
Southern/Eastern African clinic/community
(N = 4,121)
Eastern African higher-risk
(N = 1,942)
Total (N =
13,072)
Missing 1,013 1,182 1,183 3,378
Baseline contraception
Non-hormonal 2,286 (32.8) 1,543 (37.5) 1,334 (68.9) 5,163 (39.6)
COCP 624 (8.9) 1,403 (34.1) 224 (11.6) 2,251 (17.3)
DMPA 2,234 (32.0) 1,148 (27.9) 378 (19.5) 3,760 (28.9)
Neten 1,835 (26.3) 16 (0.4) 0 (0.00) 1,851 (14.2)
Total 6,979 (99.6) 4,110 (99.7) 1,936 (99.7) 13,025 (99.6)
Multiple use 28 11 4 43
Missing 2 0 2 4
Data given as N (percent) or median (quartile 1–quartile 3). Ns in this table are based on all women in included studies; prevalence estimates for each infection are based
on the subset of women who were tested for that infection.
Time period to define new partnership varied by study and was either last month or last 3 months.
Time period to define concurrency varied by study and was either current, last month, or last 3 months.
COCP, combined oral contraceptive pill; DMPA, depot medroxyprogesterone acetate; Neten, norethisterone enanthate.
https://doi.org/10.1371/journal.pmed.1002511.t002
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Table 3. Baseline characteristics by region/population type among participants aged 25–49 years.
Characteristic South African clinic/community
(N = 13,556)
Southern/Eastern African clinic/
community (N = 6,806)
Eastern African higher-risk
(N = 3,684)
Total (N =
24,046)
Sociodemographics
Age 36 (31–41) 30 (27–34) 31 (27–35) 34 (28–39)
Education
No school 740 (6.9) 389 (5.7) 334 (9.8) 1,463 (6.9)
Primary incomplete 1,974 (18.0) 1,292 (19.0) 796 (23.3) 4,062 (19.2)
Primary complete 1,058 (9.7) 1,538 (22.6) 1,763 (51.6) 4,359 (20.6)
Secondary incomplete 4,581 (41.9) 3,048 (44.8) 363 (10.6) 7,992 (37.8)
Secondary complete 2,026 (18.5) 371 (5.5) 105 (3.1) 2,502 (11.8)
Tertiary level 562 (5.1) 168 (2.5) 58 (1.7) 788 (3.7)
Total 10,941 (80.7) 6,806 (100) 3,419 (92.8) 21,166 (88.0)
Missing 2,615 0 265 2,880
Married/living with
partner
Yes 6,543 (48.3) 6,421 (94.3) 889 (24.1) 13,853 (57.6)
No 7,008 (51.7) 385 (5.7) 2,794 (75.9) 10,187 (42.4)
Total 13,551 (99.9) 6,806 (100) 3,683 (99.9) 24,040 (99.9)
Missing 5 0 1 6
Employed
Yes 2,911 (26.5) 2,659 (39.1) 3,412 (99.8) 8,982 (42.3)
No 8,076 (73.5) 4,147 (60.9) 7 (0.2) 12,230 (57.7)
Total 10,987 (81.1) 6,806 (100) 3,419 (92.8) 21,212 (88.2)
Missing 2,569 0 265 2,834
Number of live births 3 (2–4) 3 (2–4) 2 (1–4) 3 (2–4)
Sexual behaviors
Condom use at last sex
Yes 4,776 (54.6) 2,653 (48.8) 880 (34.6) 8,309 (49.7)
No 3,967 (45.4) 2,789 (51.3) 1,665 (65.4) 8,421 (50.3)
Total 8,743 (64.5) 5,442 (80.0) 2,545 (69.1) 16,730 (69.6)
Missing 4,813 1,364 1,139 7,316
Age at first sex 17 (16–18) 17 (17–20) 17 (15–18) 17 (16–18)
Coital frequency in past
month
6 (2–12) 12 (6–16) 4 (2–8) 8 (4–12)
Number of lifetime
partners
3 (2–5) 1 (1–2) 5 (3–8) 3 (2–5)
New partner
Yes 99 (2.4) 50 (1.3) 138 (85.2) 287 (3.6)
No 3,924 (97.5) 3,854 (98.7) 24 (14.8) 7,802 (96.5)
Total 4,023 (29.7) 3,904 (57.4) 162 (4.4) 8,089 (33.6)
Missing 9,533 2,902 3,522 15,957
Concurrent partner
Yes 369 (3.1) 180 (4.0) 273 (18.0) 822 (4.6)
No 11,663 (96.9) 4,320 (96.0) 1,246 (82.0) 17,229 (95.5)
Total 12,032 (88.8) 4,500 (66.1) 1,519 (41.2) 18,051 (75.1)
Missing 1,524 2,306 2,165 5,995
Baseline contraception
Non-hormonal 7,702 (57.1) 2,927 (43.2) 2,418 (65.0) 13,047 (54.5)
COCP 1,097 (8.1) 2,038 (30.0) 449 (12.2) 3,584 (15.0)
(Continued)
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aged 25–49 years were similar to those in younger populations, but were more heterogeneous
(Fig 8).
The 17 studies included in the estimation of high-titer, active infectious syphilis prevalence are
a subgroup of the studies included in the estimation of overall syphilis prevalence; summary esti-
mates of overall syphilis prevalence limited to these 17 studies are provided in S9 and S10 Figs.
Trichomoniasis. For both age groups, there was high heterogeneity in estimates of tricho-
moniasis prevalence across all strata (Figs 9 and 10). For example, among 15–24-year-olds in
higher-risk populations in Eastern Africa, estimates ranged from 6.6% to 29.7% (summary
estimate: 12.7% [95% CI: 7.5%, 20.6%]; I2 = 93.1%), and among 25–29-year-olds in the South
African clinic/community-based populations, estimates ranged from 1.9% to 28.6% (summary
estimate: 8.6% [95% CI: 6.5%, 11.5%]; I2 = 95.2%).
HSV-2. In general, HSV-2 prevalence was high among 15–24-year-olds, ranging from
31.9% to 53.7% in the South African clinic/community-based populations (summary estimate:
39.3% [95% CI: 34.3%, 44.6%]; I2 = 88.8%), 33.7% to 78.6% in Southern/Eastern African clinic/
community-based populations (summary estimate: 46.8% [95% CI: 38.2%, 55.6%]; I2 =
95.4%), and 45.7% to 65.9% in the higher-risk populations in Eastern Africa (summary esti-
mate: 56.3% [95% CI: 49.2%, 63.1%]; I2 = 87.6%) (Fig 11).
As expected due to the lifelong nature of HSV-2 infection, prevalence of HSV-2 was even
higher among women aged 25–49 years (Fig 12). In the South African clinic/community-
based populations, the summary estimate was 77.8% (95% CI: 75.6%, 79.9%; I2 = 49.2%), simi-
lar to summary estimates in Southern/Eastern African clinic/community-based populations
(70.0% [95% CI: 61.8%, 77.1%]; I2 = 97.2%) and in the higher-risk populations in Eastern
Africa (83.3% [95% CI: 79.3%, 86.6%]; I2 = 86.2%) (Fig 12).
Bacterial vaginosis. Among 15–24-year-olds in the South African clinic/community-
based populations, the summary estimate for BV prevalence was 42.1% (95% CI: 35.6%, 49.0%;
I2 = 90.0%), similar to the summary estimates in Southern/Eastern African clinic/community-
based populations (35.2% [95% CI: 27.7%, 43.6%]; I2 = 93.3%) and in the higher-risk popula-
tions in Eastern Africa (49.5% [95% CI: 42.2%, 56.8%]; I2 = 90.0%) (Fig 13). Prevalence was
similar among women aged 25–49 years, with high heterogeneity across studies (Fig 14).
Prevalence estimates for co-infection
Patterns of co-infection among women tested for at least 2 infections at baseline varied across
STI/BV combinations (Tables 4–9). In general, women with a specific infection had a higher
Table 3. (Continued)
Characteristic South African clinic/community
(N = 13,556)
Southern/Eastern African clinic/
community (N = 6,806)
Eastern African higher-risk
(N = 3,684)
Total (N =
24,046)
DMPA 3,391 (25.1) 1,768 (26.1) 803 (21.9) 5,962 (24.9)
Neten 1,298 (9.6) 51 (0.8) 0 (0.00) 1,349 (5.6)
Total 13,488 (99.5) 6,784 (99.7) 3,670 (99.6) 23,942 (99.6)
Multiple use 20 22 9 51
Missing 48 0 5 53
Data given as N (percent) or median (quartile 1–quartile 3). Ns in this table are based on all women in included studies; prevalence estimates for each infection are based
on the subset of women who were tested for that infection.
Time period to define new partnership varied by study and was either last month or last 3 months.
Time period to define concurrency varied by study and was either current, last month, or last 3 months.
COCP, combined oral contraceptive pill; DMPA, depot medroxyprogesterone acetate; Neten, norethisterone enanthate.
https://doi.org/10.1371/journal.pmed.1002511.t003
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prevalence of another infection than women without this infection. For example, the overall
estimated prevalence of chlamydia among young women in South African clinic/community-
based populations was 15.1%, but chlamydia prevalence among women infected with another
infection ranged from 16.3% (among women with HSV-2) to 38.7% (among women with gon-
orrhea; Table 4). For some infections, differences were not prominent. For example, the overall
prevalence of high-titer, active syphilis among older women in South African clinic/commu-
nity-based populations did not vary substantially by co-infection status (Table 5).
Fig 1. Chlamydia prevalence among 15–24-year-olds. The area of the marker is proportional to the square root of the sample size. Studies with
no estimate presented did not meet the inclusion criteria for this infection and age group. Year presented is the median year that baseline data
were collected during the study. Includes studies of HIV-discordant couples. E Africa, Eastern Africa; SA, South Africa; S/E Africa, Southern
and Eastern Africa.
https://doi.org/10.1371/journal.pmed.1002511.g001
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Heterogeneity across studies varied widely by STI/BV combination; overall, 60% of estimates
had low heterogeneity, 15% had mild/moderate heterogeneity, and 25% had high
heterogeneity.
Some of the most striking findings were related to chlamydia/gonorrhea co-infection.
Among women with chlamydia at baseline, the estimated prevalence of co-infection with gon-
orrhea was about 10%–20%. Among women with gonorrhea at baseline, estimated prevalence
of co-infection with chlamydia varied by population type and age group: estimated co-infec-
tion prevalence was about 30%–40% among younger and older women in South African
Fig 2. Chlamydia prevalence among 25–49-year-olds. The area of the marker is proportional to the square root of the sample size. Studies with
no estimate presented did not meet the inclusion criteria for this infection and age group. Year presented is the median year that baseline data
were collected during the study. Includes studies of HIV-discordant couples. E Africa, Eastern Africa; SA, South Africa; S/E Africa, Southern
and Eastern Africa.
https://doi.org/10.1371/journal.pmed.1002511.g002
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clinic/community-based populations (Tables 4 and 5) and was lower (about 10%) among
older women in Southern/Eastern African clinic/community-based populations (Table 7) and
older women in higher-risk populations in Eastern Africa (Table 9).
Discussion
In this IPD meta-analysis, we combined data from 18 prospective HIV prevention studies rep-
resenting over 37,000 women in sub-Saharan Africa to estimate prevalence of chlamydia, gon-
orrhea, syphilis, trichomoniasis, HSV-2, and BV. We observed age-, region- and population-
Fig 3. Gonorrhea prevalence among 15–24-year-olds. The area of the marker is proportional to the square root of the sample size. Studies with
no estimate presented did not meet the inclusion criteria for this infection and age group. Year presented is the median year that baseline data
were collected during the study. Includes studies of HIV-discordant couples. E Africa, Eastern Africa; SA, South Africa; S/E Africa, Southern
and Eastern Africa.
https://doi.org/10.1371/journal.pmed.1002511.g003
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specific patterns in the prevalence of these infections, including higher prevalence of STIs
among younger (15–24-year-old) than older (25–49-year-old) women, generally higher STI
prevalence in clinic/community-based populations in South Africa than among similar popu-
lations elsewhere in Southern/Eastern Africa, and notably greater prevalence among higher-
risk populations for certain STIs (e.g., gonorrhea and syphilis), but not for others (e.g., HSV-2
and BV, which had high prevalence across all population types).
A major strength of this analysis is that it provides important information on STI and BV
prevalence that would not otherwise be readily available through literature searches of
Fig 4. Gonorrhea prevalence among 25–49-year-olds. The area of the marker is proportional to the square root of the sample size. Studies with
no estimate presented did not meet the inclusion criteria for this infection and age group. Year presented is the median year that baseline data
were collected during the study. Includes studies of HIV-discordant couples. E Africa, Eastern Africa; SA, South Africa; S/E Africa, Southern
and Eastern Africa.
https://doi.org/10.1371/journal.pmed.1002511.g004
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published data. Few of our included studies had published detailed results about STI or BV.
None of the data from the included studies were identified through the literature search pro-
cess used to generate the 2008 and 2012 WHO global curable STI estimates [1,37], because
they included only higher-risk populations, they were published outside the time frames of the
literature searches, they were not identified in the searches, or the published papers did not
provide enough information (e.g., estimates not stratified by age group, sex, or country/region)
to include in the WHO estimates. One study that initially did not have enough STI informa-
tion in the published paper to include in the WHO 2012 estimates was later identified during
Fig 5. Syphilis overall prevalence among 15–24-year-olds. The area of the marker is proportional to the square root of the sample size. Studies
with no estimate presented did not meet the inclusion criteria for this infection and age group. Year presented is the median year that baseline
data were collected during the study. Includes studies of HIV-discordant couples. E Africa, Eastern Africa; SA, South Africa; S/E Africa,
Southern and Eastern Africa.
https://doi.org/10.1371/journal.pmed.1002511.g005
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this STI IPD meta-analysis and subsequently incorporated [30,31]. Combining STI/BV data
from a large number of studies allowed us to estimate prevalence by age and population type
more precisely for distinct regions within sub-Saharan Africa.
While this IPD meta-analysis provides a unique opportunity to strengthen understanding
of the epidemiology of STIs/BV among sub-Saharan African women, several limitations need
to be considered. First, the studies included in the HC-HIV meta-analysis dataset were not
specifically selected to assess STI/BV prevalence, and should be considered a convenience sam-
ple of studies. There may have been additional studies from the region that did not meet
Fig 6. Syphilis overall prevalence among 25–49-year-olds. The area of the marker is proportional to the square root of the sample size. Studies
with no estimate presented did not meet the inclusion criteria for this infection and age group. Year presented is the median year that baseline
data were collected during the study. Includes studies of HIV-discordant couples. E Africa, Eastern Africa; SA, South Africa; S/E Africa,
Southern and Eastern Africa.
https://doi.org/10.1371/journal.pmed.1002511.g006
STIs/BV among women in Sub-Saharan Africa
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1002511 February 27, 2018 18 / 38
inclusion criteria for the HC-HIV meta-analysis, but contained STI/BV data, including data
for men. In addition, the women in these studies were not randomly sampled from the popula-
tions they represent. Women enrolled from clinical settings in particular may be more likely to
be symptomatic or recently exposed to an STI, which would tend to overestimate STI preva-
lence. Some studies only enrolled women in clinic/community settings who reported recent
sexual activity or more than 1 partner in the recent past [33]. Conversely, because all included
studies were prospective evaluations of HIV acquisition, women included in this baseline eval-
uation were all HIV-negative. Thus, we may have underestimated STI/BV prevalence in
Fig 7. High-titer syphilis prevalence among 15–24-year-olds. The area of the marker is proportional to the square root of the sample size.
Studies with no estimate presented did not meet the inclusion criteria for this infection and age group. Year presented is the median year that
baseline data were collected during the study. Includes studies of HIV-discordant couples. E Africa, Eastern Africa; SA, South Africa; S/E Africa,
Southern and Eastern Africa.
https://doi.org/10.1371/journal.pmed.1002511.g007
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communities with high HIV prevalence (such as in South Africa), where HIV-negative women
may be at lower STI/HIV risk than others in their communities. Reassuringly, the prevalences
of curable STIs we observed in clinic/community-based populations, especially in Southern/
Eastern Africa, were similar to WHO 2012 estimates for African women (which were limited
to general populations) [1]. Another limitation of this meta-analysis is that it included some
studies that are more than 15 years old. Summary estimates could be biased if prevalence has
changed over time. Evidence of temporal trends in the prevalence of STIs/BV in LMICs is lim-
ited, in part due to lack of standardized surveillance systems and differing methodology for
Fig 8. High-titer syphilis prevalence among 25–49-year-olds. The area of the marker is proportional to the square root of the sample size.
Studies with no estimate presented did not meet the inclusion criteria for this infection and age group. Year presented is the median year that
baseline data were collected during the study. Includes studies of HIV-discordant couples. E Africa, Eastern Africa; SA, South Africa; S/E Africa,
Southern and Eastern Africa.
https://doi.org/10.1371/journal.pmed.1002511.g008
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repeated sets of regional estimates [1]. Available data from a few large studies have not shown
clear evidence of changing epidemiology over the last two decades, beyond methodological
issues in the estimation process [1–3]. Aside from syphilis—for which available rapid diagnos-
tic tests and concerted efforts to screen and treat pregnant women to avert mother-to-child
transmission have resulted in likely declines over time [1,38]—the other STIs and BV lack
clearly effective population-level interventions in these settings. This provides confidence that
even though some studies in this IPD meta-analysis are older, the data provide a general idea
Fig 9. Trichomoniasis prevalence among 15–24-year-olds. The area of the marker is proportional to the square root of the sample size. Studies
with no estimate presented did not meet the inclusion criteria for this infection and age group. Year presented is the median year that baseline
data were collected during the study. Includes studies of HIV-discordant couples. E Africa, Eastern Africa; SA, South Africa; S/E Africa,
Southern and Eastern Africa.
https://doi.org/10.1371/journal.pmed.1002511.g009
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of the overall STI epidemic in these regions. Future research could combine these data with
additional data points to further the understanding of global trends over time.
We observed high heterogeneity across studies when calculating summary estimates for
STI/BV prevalence in some populations. Observed heterogeneity can reflect differences in
study design, setting, sample size, and recruitment strategies between studies. We present sum-
mary estimates irrespective of the degree of between-study heterogeneity to facilitate the com-
parison of overall patterns between the population groups for each infection; however,
observed heterogeneity should be taken into account when interpreting findings. For example,
Fig 10. Trichomoniasis prevalence among 25–49-year-olds. The area of the marker is proportional to the square root of the sample size. Studies
with no estimate presented did not meet the inclusion criteria for this infection and age group. Year presented is the median year that baseline
data were collected during the study. Includes studies of HIV-discordant couples. E Africa, Eastern Africa; SA, South Africa; S/E Africa,
Southern and Eastern Africa.
https://doi.org/10.1371/journal.pmed.1002511.g010
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differences in test technology might explain some of the heterogeneity for some infections. We
attempted to minimize this by excluding studies with less accurate tests for a particular STI or
BV (e.g., studies that diagnosed BV based only on Amsel clinical criteria [39]). For some STIs,
however, results from diagnostic tests with varying levels of sensitivity and specificity were
included. Some of the most noticeable heterogeneity was observed among trichomoniasis esti-
mates, for which a large number of studies used only wet mount, which is notably insensitive
[40]. For HSV-2, although all included studies used EIAs, some studies used EIAs with lower
specificity [41]. For chlamydia and gonorrhea, prevalence estimates were relatively consistent
across studies despite some high I2 values. For syphilis estimates, heterogeneity was less pro-
nounced. To refine prevalence estimates, future work could consider additional investigation
into heterogeneity by diagnostic test type. Finally, studies that were conducted in multiple
regions or among multiple population types were split into sub-studies; it is possible that esti-
mates from these sub-studies are not independent.
Fig 11. Herpes simplex virus type 2 prevalence among 15–24-year-olds. The area of the marker is proportional to the square root of the sample size. Studies with no
estimate presented did not meet the inclusion criteria for this infection and age group. Year presented is the median year that baseline data were collected during the study.
Includes studies of HIV-discordant couples. E Africa, Eastern Africa; SA, South Africa; S/E Africa, Southern and Eastern Africa.
https://doi.org/10.1371/journal.pmed.1002511.g011
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We observed several patterns that highlight important features of the STI/BV epidemics in
sub-Saharan Africa, which address the first strategic direction of the Global Strategy for STIs:
“information for focused action: the who and the where.” In terms of the “who,” across all pop-
ulations and regions, STI prevalence was generally higher among younger than older women,
except for the prevalence of antibodies to HSV-2, which increased with age. Higher STI preva-
lence among young people has been observed worldwide and highlights the need for global
efforts to improve sexual and reproductive health in adolescent girls and young women [42–
44]. Additionally, we found that women who were in HIV-discordant partnerships had similar
STI prevalence as women recruited from clinic/community-based populations, perhaps
reflecting that although these participants may be at higher risk for HIV transmission than the
general population, their risk for STIs/BV may be similar to that of clinic/community-based
populations, given that they are in stable relationships.
Fig 12. Herpes simplex virus type 2 prevalence among 25–49-year-olds. The area of the marker is proportional to the square root of the sample size. Studies with no
estimate presented did not meet the inclusion criteria for this infection and age group. Year presented is the median year that baseline data were collected during the study.
Includes studies of HIV-discordant couples. E Africa, Eastern Africa; SA, South Africa; S/E Africa, Southern and Eastern Africa.
https://doi.org/10.1371/journal.pmed.1002511.g012
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As for the “where,” we found that women enrolled from clinic or community-based settings
in South Africa had particularly high prevalence of STIs. In many cases, STI prevalence in
South African women was similar to or greater than that of populations in Eastern Africa that
were recruited from settings thought to be higher risk for HIV, such as women who report
transactional sex. These findings are consistent with other studies in South Africa showing
high prevalence of infections like chlamydia and gonorrhea [45,46]. This is particularly con-
cerning given the likely increased risk of HIV acquisition posed by these inflammatory STIs
[47,48]. Because of variability in how studies measured sexual behavior, we were unable to
fully explore reasons for differences in STI prevalence across regions. South African women in
the included studies were, however, less likely to be married or living with a partner compared
with Southern/Eastern African women, although they were more likely than other groups to
report condom use at last sex [49,50]. Additional work, such as research that incorporates
Fig 13. Bacterial vaginosis prevalence among 15–24-year-olds. The area of the marker is proportional to the square root of the sample size. Studies with no estimate
presented did not meet the inclusion criteria for this infection and age group. Year presented is the median year that baseline data were collected during the study.
Includes studies of HIV-discordant couples. E Africa, Eastern Africa; SA, South Africa; S/E Africa, Southern and Eastern Africa.
https://doi.org/10.1371/journal.pmed.1002511.g013
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anthropological and other qualitative methodologies, could help elucidate the cultural and
behavioral drivers of observed differences between these populations.
The estimated prevalence of chlamydia in clinic/community populations in Southern/East-
ern Africa was very similar to estimates from high-income countries in Europe and in the
United States, including countries with well-established chlamydia control programs [51,52].
HSV-2 and BV prevalence was relatively high across all regions and population types. Gonor-
rhea and syphilis, on the other hand, were primarily concentrated among women recruited
from settings thought to be at higher risk for HIV, which in this study were all in Eastern
Africa. This suggests that targeting interventions to both populations and geographic regions
may be important in addressing 2 of the 3 main areas of intervention focus for the Global
Strategy: first, controlling the spread and impact of gonorrhea, particularly to stem the threat
of gonococcal antimicrobial resistance [53], and, second, dramatically reducing mother-to-
child transmission of syphilis and HIV [54]. The third main area of intervention focus of the
Fig 14. Bacterial vaginosis prevalence among 25–49-year-olds. The area of the marker is proportional to the square root of the sample size. Studies with no estimate
presented did not meet the inclusion criteria for this infection and age group. Year presented is the median year that baseline data were collected during the study.
Includes studies of HIV-discordant couples.E Africa, Eastern Africa; SA, South Africa; S/E Africa, Southern and Eastern Africa.
https://doi.org/10.1371/journal.pmed.1002511.g014
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Table 4. Proportion of participants with each infection who are co-infected with an additional STI or BV among women aged 15–24 years in South African clinic/
community populations.
Co-infected with Infected with
Chlamydia
(N = 1,056)
Gonorrhea
(N = 316)
Syphilis, high-titer infection
(N = 22)
Trichomoniasis
(N = 559)
HSV-2
(N = 1,675)
BV
(N = 1,386)
Chlamydia
Overall prevalence: 15.1% (12.7, 17.8)
— 38.7 (28.6, 48.9)
N = 316
I2 = 56.1, P = 0.026
17.9 (0.0, 36.2)
N = 22
I2 = 0, P = 0.820
24.2 (19.5, 28.9)
N = 554
I2 = 19.7, P = 0.274
16.3 (12.7, 19.9)
N = 1,529
I2 = 56.4, P = 0.043
19.1 (14.8, 23.4)
N = 1,357
I2 = 61.7, P = 0.023
Gonorrhea
Overall prevalence: 4.6% (3.3, 6.4)
11.4 (7.2, 15.6)
N = 1,049
I2 = 67.8, P = 0.003
—- 15.3 (0.0, 30.7)
N = 22
I2 = 0, P = 0.430
9.0 (6.6, 11.4)
N = 552
I2 = 0, P = 0.617
5.8 (2.3, 9.3)
N = 1,523
I2 = 83.6, P  0.001
5.7 (3.9, 7.4)
N = 1,350
I2 = 30.6, P = 0.206
Syphilis, high-titer infection
Overall prevalence: 0.4% (0.3, 0.5)
0.5 (0.0, 1.0)
N = 878
I2 = 0, P = 1.000
1.3 (0.0, 2.7)
N = 258
I2 = 0, P = 0.870
— 0.9 (0.0, 1.8)
N = 499
I2 = 0, P = 0.998
0.5 (0.1, 0.8)
N = 1,341
I2 = 0, P = 0.666
0.6 (0.1, 1.1)
N = 946
I2 = 0, P = 0.993
Trichomoniasis
Overall prevalence: 7.9% (5.9, 10.5)
12.2 (9.7, 14.7)
N = 1,053
I2 = 20.9, P = 0.263
16.2 (12.1, 20.3)
N = 313
I2 = 0, P = 0.720
25.8 (0.3, 51.2)
N = 22
I2 = 33.5, P = 0.211
— 8.7 (5.4, 12.0)
N = 1,547
I2 = 70.2, P = 0.005
9.4 (3.6, 15.1)
N = 1,378
I2 = 92.8, P 0.001
HSV-2
Overall prevalence: 39.3% (34.4, 44.6)
45.2 (33.2, 57.3)
N = 600
I2 = 82.1, P  0.001
52.9 (45.4, 60.3)
N = 175
I2 = 0, P = 0.590
47.8 (5.6, 90.0)
N = 15
I2 = 45.2, P = 0.161
49.1 (40.1, 58.1)
N = 315
I2 = 34.2, P = 0.193
— 41.2 (37.4, 45.0)
N = 1,163
I2 = 0, P = 0.333
BV
Overall prevalence: 42.1% (35.6, 49.0)
42.1 (15.1, 69.1)
N = 934
I2 = 98.9, P  0.001
38.3 (11.7, 65.0)
N = 293
I2 = 96.5, P  0.001
38.8 (0.0, 84.6)
N = 19
I2 = 70.1, P = 0.035
38.3 (11.7, 64.9)
N = 496
I2 = 97.8, P  0.001
48.2 (37.9, 58.4)
N = 1,106
I2 = 83.3, P  0.001
—
Data are presented as percent (95% CI) infected with the column infection who are co-infected with the row infection. N is the number of participants who were
infected with the column infection and were also tested for the row infection; includes data from studies where at least 80% of all participants or at least 80% of a
randomly selected sample of enrolled participants were tested for both infections.
BV, bacterial vaginosis; HSV-2, herpes simplex virus type 2; STI, sexually transmitted infection.
https://doi.org/10.1371/journal.pmed.1002511.t004
Table 5. Proportion of participants with each infection who are co-infected with an additional STI or BV among women aged 25–49 years in South African clinic/
community populations.
Co-infected with Infected with
Chlamydia
(N = 796)
Gonorrhea
(N = 398)
Syphilis, high-titer infection
(N = 60)
Trichomoniasis
(N = 1,406)
HSV-2
(N = 4,101)
BV
(N = 1,589)
Chlamydia
Overall prevalence: 7.0% (5.5, 8.8)
— 32.4 (0.0, 69.9)
N = 398
I2 = 98.7, P  0.001
5.8 (0.0, 11.8)
N = 60
I2 = 0, P = 0.707
7.1 (4.1, 10.1)
N = 1,403
I2 = 60.6, P = 0.009
6.5 (4.3, 8.7)
N = 3,963
I2 = 76.7, P  0.001
8.8 (6.8, 10.8)
N = 1,568
I2 = 0, P = 0.306
Gonorrhea
Overall prevalence: 2.5% (1.6, 4.0)
18.5 (0.0, 57.5)
N = 793
I2 = 99.8, P  0.001
— 3.7 (0.0, 11.1)
N = 60
I2 = 0, P = 0.905
4.0 (1.4, 6.5)
N = 1,402
I2 = 64.1, P = 0.004
2.2 (0.8, 3.6)
N = 3,959
I2 = 80.1, P  0.001
2.9 (1.8, 3.9)
N = 1,562
I2 = 0, P = 0.328
Syphilis, high-titer infection
Overall prevalence: 1.0% (0.5, 2.1)
0.6 (0.0, 1.2)
N = 475
I2 = 0, P = 0.732
1.1 (0.0, 3.4)
N = 153
I2 = 0, P = 0.961
— 0.3 (0.0, 0.7)
N = 848
I2 = 0, P = 0.994
1.3 (0.5, 2.0)
N = 3,682
I2 = 34.7, P = 0.176
0.6 (0.2, 1.1)
N = 1,268
I2 = 0, P = 0.795
Trichomoniasis
Overall prevalence: 8.6% (6.5, 11.5)
11.0 (5.0, 17.1)
N = 792
I2 = 82.8, P  0.001
15.3 (11.7, 18.9)
N = 396
I2 = 0, P = 0.475
6.5 (0.0, 13.3)
N = 60
I2 = 0, P = 0.973
— 5.8 (1.6, 9.9)
N = 3,970
I2 = 94.8, P  0.001
9.5 (5.0, 14.0)
N = 1,582
I2 = 82.3, P 0.001
HSV-2
Overall prevalence: 77.8% (75.6, 79.9)
81.0 (75.1, 86.9)
N = 296
I2 = 21.2, P = 0.280
83.2 (75.9, 90.5)
N = 106
I2 = 0, P = 0.999
90.9 (82.0, 99.8)
N = 47
I2 = 0, P = 0.915
84.5 (73.5, 95.6)
N = 368
I2 = 57.8, P = 0.050
— 82.9 (81.0, 84.9)
N = 1,387
I2 = 0, P = 0.453
BV
Overall prevalence: 41.2% (34.2, 48.4)
38.9 (13.4, 64.5)
N = 508
I2 = 97.6, P  0.001
30.1 (3.1, 57.1)
N = 168
I2 = 92.5, P  0.001
26.7 (0.0, 56.8)
N = 38
I2 = 70.1, P = 0.035
49.5 (16.8, 82.3)
N = 832
I2 = 98.8, P  0.001
47.5 (37.1, 57.9)
N = 2,825
I2 = 90.3, P  0.001
—
Data are presented as percent (95% CI) infected with the column infection who are co-infected with the row infection. N is the number of participants who were
infected with the column infection and were also tested for the row infection; includes data from studies where at least 80% of all participants or at least 80% of a
randomly selected sample of enrolled participants were tested for both infections.
BV, bacterial vaginosis; HSV-2, herpes simplex virus type 2; STI, sexually transmitted infection.
https://doi.org/10.1371/journal.pmed.1002511.t005
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Table 6. Proportion of participants with each infection who are co-infected with an additional STI or BV among women aged 15–24 years in Southern/Eastern Afri-
can clinic/community populations.
Co-infected with Infected with
Chlamydia
(N = 123)
Gonorrhea
(N = 66)
Syphilis, high-titer infection
(N = 18)
Trichomoniasis
(N = 205)
HSV-2
(N = 1,341)
BV
(N = 853)
Chlamydia
Overall prevalence: 2.7% (1.5, 3.9)
— 22.9 (7.8, 37.9)
N = 66
I2 = 24.5, P = 0.225
12.0 (0.0, 31.5)
N = 17
I2 = 0, P = 0.904
5.3 (1.0, 9.6)
N = 201
I2 = 0, P = 0.465
3.6 (1.1, 6.0)
N = 1,324
I2 = 85.8, P  0.001
3.7 (2.1, 5.4)
N = 844
I2 = 33.4, P = 0.186
Gonorrhea
Overall prevalence: 1.7% (1.2, 2.6)
13.2 (6.4, 19.9)
N = 123
I2 = 0, P = 0.537
— 0.0 (0.0, 23.0)
N = 17
I2 = 0, P = 1.000
4.8 (1.4, 8.2)
N = 202
I2 = 0, P = 0.724
2.4 (1.3, 3.4)
N = 1,324
I2 = 27.2, P = 0.231
2.1 (1.1, 3.1)
N = 844
I2 = 0, P = 0.795
Syphilis, high-titer infection
Overall prevalence: 1.1% (0.3, 1.9)
6.5 (0.0, 18.4)
N = 28
I2 = 0, P = 0.997
0.0 (0.0, 21.7)
N = 19
I2 = 0, P = 1.000
— 2.6 (0.0, 6.7)
N = 98
I2 = 0, P = 1.000
1.7 (0.6, 2.9)
N = 516
I2 = 0, P = 0.672
1.8 (0.0, 3.5)
N = 222
I2 = 0, P = 1.000
Trichomoniasis
Overall prevalence: 6.7% (4.3, 10.1)
10.3 (4.2, 16.5)
N = 123
I2 = 0, P = 0.938
17.3 (7.0, 27.6)
N = 66
I2 = 0, P = 0.878
12.4 (0.0, 31.5)
N = 17
I2 = 0, P = 0.942
— 6.9 (3.9, 9.8)
N = 1,339
I2 = 79.1, P  0.001
8.9 (4.8, 13.0)
N = 852
I2 = 78.4, P  0.001
HSV-2
Overall prevalence: 46.8% (38.2, 55.6)
56.5 (47.0, 65.9)
N = 109
I2 = 0, P = 0.736
62.7 (49.3, 76.0)
N = 56
I2 = 0, P = 0.500
72.6 (49.9, 95.4)
N = 17
I2 = 0, P = 0.680
65.3 (47.3, 83.3)
N = 144
I2 = 83.4, P  0.001
— 56.9 (39.3, 74.6)
N = 769
I2 = 95.1, P  0.001
BV
Overall prevalence: 35.2% (27.7, 43.6)
39.9 (23.8, 55.9)
N = 100
I2 = 45.4, P = 0.103
30.9 (18.8, 42.9)
N = 58
I2 = 0, P = 0.470
29.5 (3.1, 56.0)
N = 13
I2 = 0, P = 0.519
45.8 (26.4, 65.1)
N = 156
I2 = 86.0, P  0.001
35.1 (27.3, 43.0)
N = 1,120
I2 = 86.0, P  0.001
—
Data are presented as percent (95% CI) infected with the column infection who are co-infected with the row infection. N is the number of participants who were
infected with the column infection and were also tested for the row infection; includes data from studies where at least 80% of all participants or at least 80% of a
randomly selected sample of enrolled participants were tested for both infections.
BV, bacterial vaginosis; HSV-2, herpes simplex virus type 2; STI, sexually transmitted infection.
https://doi.org/10.1371/journal.pmed.1002511.t006
Table 7. Proportion of participants with each infection who are co-infected with an additional STI or BV among women aged 25–49 years in Southern/Eastern Afri-
can clinic/community populations.
Co-infected with Infected with
Chlamydia
(N = 82)
Gonorrhea
(N = 77)
Syphilis, high-titer infection
(N = 34)
Trichomoniasis
(N = 357)
HSV-2
(N = 3,458)
BV
(N = 1,297)
Chlamydia
Overall prevalence: 1.2% (0.8, 1.7)
— 9.8 (0.5, 19.2)
N = 77
I2 = 0, P = 0.770
0.0 (0.0, 13.8)
N = 31
I2 = 0, P = 1.000
2.1 (0.3, 3.9)
N = 354
I2 = 0, P = 0.984
1.0 (0.3, 1.6)
N = 3,365
I2 = 76.8, P  0.001
1.3 (0.4, 2.3)
N = 1,273
I2 = 59.5, P = 0.030
Gonorrhea
Overall prevalence: 0.9% (0.5, 1.6)
10.0 (0.9, 19.1)
N = 82
I2 = 0, P = 0.806
— 2.4 (0.0, 16.1)
N = 31
I2 = 0, P = 0.830
2.2 (0.3, 4.1)
N = 354
I2 = 0, P = 0.843
1.5 (0.6, 2.4)
N = 3,366
I2 = 84.9, P  0.001
1.8 (0.5, 3.1)
N = 1,273
I2 = 69.9, P = 0.005
Syphilis, high-titer infection
Overall prevalence: 0.9% (0.2, 1.7)
0.0 (0.0, 17.2)
N = 27
I2 = 0, P = 1.000
5.7 (0.0, 18.3)
N = 25
I2 = 0, P = 1.000
— 1.7 (0.0, 4.0)
N = 224
I2 = 0, P = 0.976
1.3 (0.2, 2.4)
N = 1,740
I2 = 61.6, P = 0.023
1.3 (0.3, 2.3)
N = 534
I2 = 0, P = 0.684
Trichomoniasis
Overall prevalence: 5.8% (4.0, 8.4)
5.4 (0.2, 10.5)
N = 82
I2 = 0, P = 0.931
10.1 (2.4, 17.9)
N = 77
I2 = 0, P = 0.436
13.1 (0.0, 26.1)
N = 32
I2 = 0, P = 0.922
— 6.0 (3.6, 8.3)
N = 3,425
I2 = 89.4, P  0.001
8.6 (4.6, 12.5)
N = 1,297
I2 = 86.7, p P  0.001
HSV-2
Overall prevalence: 70.0% (61.8, 77.1)
59.5 (47.6, 71.4)
N = 68
I2 = 0, P = 0.652
84.3 (75.2, 93.5)
N = 69
I2 = 0, P = 0.956
85.2 (70.4, 100.0)
N = 30
I2 = 0, P = 0.646
84.9 (75.2, 94.6)
N = 245
I2 = 80.8, P  0.001
— 75.1 (62.5, 87.8)
N = 1,143
I2 = 95.4, P  0.001
BV
Overall prevalence: 33.3% (24.7, 43.1)
39.3 (20.2, 58.4)
N = 60
I2 = 46.5, P = 0.096
45.9 (33.6, 58.2)
N = 66
I2 = 0, P = 0.734
36.9 (18.0, 55.8)
N = 27
I2 = 0, P = 0.891
45.2 (28.7, 61.7)
N = 241
I2 = 86.3, P  0.001
29.9 (21.3, 38.5)
N = 2,736
I2 = 96.0, P  0.001
—
Data are presented as percent (95% CI) infected with the column infection who are co-infected with the row infection. N is the number of participants who were
infected with the column infection and were also tested for the row infection; includes data from studies where at least 80% of all participants or at least 80% of a
randomly selected sample of enrolled participants were tested for both infections.
BV, bacterial vaginosis; HSV-2, herpes simplex virus type 2; STI, sexually transmitted infection.
https://doi.org/10.1371/journal.pmed.1002511.t007
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Global Strategy is fully utilizing HPV vaccines; however, too few studies in the HC-HIV data-
set collected information on HPV infection for us to evaluate this important STI.
Implications
Innovative approaches to obtaining better data on the STI burden are critical for developing
and implementing prevention interventions, and monitoring evidence of program impact.
Global STI management guidelines are currently being updated [55], and key decisions about
the use of syndromic management (the use of presumptive treatment for symptomatic people
without the use of laboratory tests) are dependent on accurate STI and BV prevalence data in
different settings [56]. Our assessment of co-infections among the STIs can also help guide
decision-making related to treatment. These prevalence data can also provide critical inputs to
guide decision-making about STI prevention and control programs in different settings, e.g.,
congenital syphilis elimination efforts, the role of STI laboratory testing and treatment, includ-
ing screening, and potential cost-effectiveness.
STI prevalence data also allow more accurate assessment of the need and potential impact
of future interventions. A global roadmap for accelerating development of new STI vaccines
outlined how better data on STI burden in LMICs are critical for assessing more accurately the
predicted impact of STI vaccines, developing investment cases for vaccine development, and
Table 8. Proportion of participants with each infection who are co-infected with an additional STI or BV among women aged 15–24 years in Eastern African
higher-risk populations.
Co-infected with Infected with
Chlamydia
(N = 147)
Gonorrhea
(N = 159)
Syphilis, high-titer
infection
(N = 85)
Trichomoniasis
(N = 208)
HSV-2
(N = 979)
BV
(N = 909)
Chlamydia
Overall prevalence: 10.3% (7.4,
14.1)
— 19.1 (9.9, 28.4)
N = 156
I2 = 47.6,
P = 0.076
6.9 (0.7, 13.1)
N = 85
I2 = 0, P = 0.968
7.0 (3.5, 10.5)
N = 205
I2 = 0, P = 0.516
9.3 (5.0, 13.6)
N = 913
I2 = 82.1, P 
0.001
10.4 (6.6, 14.3)
N = 867
I2 = 74.4, P
0.001
Gonorrhea
Overall prevalence: 8.2% (5.8,
11.6)
20.2 (12.7, 27.7)
N = 147
I2 = 23.4,
P = 0.258
— 9.2 (2.6, 15.7)
N = 85
I2 = 0, P = 0.700
10.9 (4.2, 17.6)
N = 208
I2 = 61.8, P = 0.023
11.5 (7.6, 15.3)
N = 972
I2 = 71.3,
P = 0.004
9.6 (6.3, 12.9)
N = 909
I2 = 67.6,
P = 0.005
Syphilis, high-titer infection
Overall prevalence: 4.5% (3.6, 5.5)
4.1 (0.1, 8.0)
N = 147
I2 = 0, P = 0.968
5.1 (1.3, 8.9)
N = 158
I2 = 0, P = 0.679
— 9.0 (5.1, 12.9)
N = 207
I2 = 0, P = 0.510
5.4 (4.0, 6.8)
N = 972
I2 = 0, P = 0.735
5.5 (4.0, 7.0)
N = 904
I2 = 0, P = 0.859
Trichomoniasis
Overall prevalence: 12.7% (7.5,
20.6)
11.3 (3.8, 18.8)
N = 131
I2 = 46.3,
P = 0.114
18.2 (7.4, 29.0)
N = 140
I2 = 68.4,
P = 0.007
29.8 (18.9, 40.7)
N = 73
I2 = 0, P = 0.976
— 12.7 (7.1, 18.2)
N = 827
I2 = 79.6, P 
0.001
15.6 (8.7, 22.4)
N = 768
I2 = 86.2, P
0.001
HSV-2
Overall prevalence: 56.3% (49.2,
63.1)
59.2 (50.4, 68.1)
N = 122
I2 = 0, P = 0.780
79.5 (72.8, 86.2)
N = 141
I2 = 0, P = 0.682
78.4 (68.5, 88.3)
N = 71
I2 = 0, P = 0.941
66.5 (58.6, 74.3)
N = 142
I2 = 0, P = 0.841
— 66.8 (48.5, 85.0)
N = 905
I2 = 98.0, P
0.001
BV
Overall prevalence: 49.5% (42.2,
56.8)
58.2 (50.2, 66.2)
N = 147
I2 = 0, P = 0.440
57.3 (46.9, 67.6)
N = 159
I2 = 41.7,
P = 0.113
64.2 (52.0, 76.4)
N = 85
I2 = 27.2, P = 0.221
58.4 (43.3, 73.4)
N = 207
I2 = 81.1, P
0.001
50.8 (44.2, 57.4)
N = 963
I2 = 75.3,
P = 0.001
—
Data are presented as percent (95% CI) infected with the column infection who are co-infected with the row infection. N is the number of participants who were
infected with the column infection and were also tested for the row infection; includes data from studies where at least 80% of all participants or at least 80% of a
randomly selected sample of enrolled participants were tested for both infections.
BV, bacterial vaginosis; HSV-2, herpes simplex virus type 2; STI, sexually transmitted infection.
https://doi.org/10.1371/journal.pmed.1002511.t008
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guiding future vaccine implementation and evaluation [57,58]. Work on a vaccine against
HSV is well underway [59], which is crucial given the HSV-2 prevalence of roughly 70%–80%
among 25–49-year-old women in this analysis and the notable increased risk of HIV due to
HSV [60]. Proof-of-principle findings from a study of how the meningococcal B vaccine might
impact gonorrhea are also intriguing [61]. Given augmentation of HIV risk with all STIs as
well as BV, and other major reproductive health outcomes such as infertility, not only STI vac-
cines but multipurpose prevention technologies such as vaginal microbicides and the role of
expanded screening through point-of-care tests should also be explored [60,62].
Collecting better information on STI prevalence and incidence is the first key strategic
direction of the new Global Strategy [4]. Given resource and logistical constraints, de novo
dedicated STI prevalence studies may not be realistic in many settings, particularly in sub-
Saharan Africa, where the impact of STIs and their consequences may be greatest [63]. This
IPD meta-analysis leverages existing STI data to fill this unmet need and offers a new approach
to obtaining critically needed information on the epidemiology of STIs in LMICs. In addition
to seeking opportunities to add STI laboratory testing to surveillance studies and clinical trials
from the outset, this methodology can be applied to other regions and populations, including
men, to further inform global estimates of STI and BV burden.
Table 9. Proportion of participants with each infection who are co-infected with an additional STI or BV among women aged 25–49 years in Eastern African
higher-risk populations.
Co-infected with Infected with
Chlamydia
(N = 184)
Gonorrhea
(N = 192)
Syphilis, high-titer
infection
(N = 114)
Trichomoniasis
(N = 331)
HSV-2
(N = 2,604)
BV
(N = 1,582)
Chlamydia
Overall prevalence: 6.2% (4.7, 8.2)
— 9.6 (5.4, 13.8)
N = 189
I2 = 0, P = 0.541
8.2 (2.1, 14.3)
N = 107
I2 = 0, P = 0.492
7.0 (4.2, 9.8)
N = 323
I2 = 0, P = 0.730
5.4 (3.6, 7.3)
N = 2,411
I2 = 76.2, P
0.001
5.9 (4.0, 7.8)
N = 1,510
I2 = 60.6,
P = 0.019
Gonorrhea
Overall prevalence: 5.2% (3.9, 7.0)
9.3 (5.1, 13.6)
N = 184
I2 = 0, P = 0.628
— 5.7 (1.3, 10.1)
N = 113
I2 = 0, P = 0.991
5.8 (3.2, 8.5)
N = 331
I2 = 0, P = 0.853
5.9 (4.8, 7.1)
N = 2,583
I2 = 36.8,
P = 0.161
6.1 (3.9, 8.4)
N = 1,573
I2 = 74.2, P
0.001
Syphilis, high-titer infection
Overall prevalence: 2.8% (1.9, 4.2)
4.5 (1.1, 8.0)
N = 183
I2 = 0, P = 0.722
4.0 (0.9, 7.0)
N = 192
I2 = 0, P = 0.994
— 4.0 (1.7, 6.4)
N = 329
I2 = 0, P = 0.706
2.9 (1.3, 4.5)
N = 2,585
I2 = 87.6, P
0.001
3.1 (1.8, 4.5)
N = 1,569
I2 = 61.8,
P = 0.015
Trichomoniasis
Overall prevalence: 10.0% (5.7,
17.1)
14.2 (5.9, 22.5)
N = 153
I2 = 53.7,
P = 0.071
11.1 (3.0, 19.2)
N = 168
I2 = 60.3,
P = 0.028
16.3 (1.8, 30.7)
N = 85
I2 = 58.2, P = 0.035
— 8.4 (6.2, 10.6)
N = 2,109
I2 = 65.0,
P = 0.014
14.2 (8.5, 19.8)
N = 1,346
I2 = 88.0, P
0.001
HSV-2
Overall prevalence: 83.3% (79.3,
86.6)
83.1 (76.2, 90.0)
N = 148
I2 = 21.3,
P = 0.279
89.9 (85.1, 94.6)
N = 178
I2 = 0, P = 0.342
96.2 (92.0, 100.0)
N = 98
I2 = 0, P = 0.868
89.3 (83.0, 95.7)
N = 194
I2 = 50.0,
P = 0.091
— 88.6 (82.6, 94.6)
N = 1,577
I2 = 95.6, P
0.001
BV
Overall prevalence: 44.1% (39.0,
49.4)
47.9 (37.1, 58.7)
N = 182
I2 = 53.3,
P = 0.058
51.6 (42.1, 61.1)
N = 189
I2 = 41.3,
P = 0.116
51.1 (41.8, 60.5)
N = 112
I2 = 0, P = 0.489
59.9 (53.4, 66.5)
N = 329
I2 = 27.4,
P = 0.229
43.7 (40.3, 47.1)
N = 2,569
I2 = 66.6,
P = 0.011
—
Data are presented as percent (95% CI) infected with the column infection who are co-infected with the row infection. N is the number of participants who were
infected with the column infection and were also tested for the row infection; includes data from studies where at least 80% of all participants or at least 80% of a
randomly selected sample of enrolled participants were tested for both infections.
BV, bacterial vaginosis; HSV-2, herpes simplex virus type 2; STI, sexually transmitted infection.
https://doi.org/10.1371/journal.pmed.1002511.t009
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Supporting information
S1 Fig. Chlamydia prevalence among 15–24-year-olds, stratified by initial region and pop-
ulation type category. E Africa, Eastern Africa; SA, South Africa; S Africa, Southern Africa.
The area of the marker is proportional to the square root of the sample size. Studies with no
estimate presented did not meet the inclusion criteria for this infection and age group. Year
presented is the median year that baseline data were collected during the study.
(TIF)
S2 Fig. Chlamydia prevalence among 25–49-year-olds, stratified by initial region and pop-
ulation type category. E Africa, Eastern Africa; SA, South Africa; S Africa, Southern Africa.
The area of the marker is proportional to the square root of the sample size. Studies with no
estimate presented did not meet the inclusion criteria for this infection and age group. Year
presented is the median year that baseline data were collected during the study.
(TIF)
S3 Fig. Gonorrhea prevalence among 15–24-year-olds, stratified by initial region and pop-
ulation type category. E Africa, Eastern Africa; SA, South Africa; S Africa, Southern Africa.
The area of the marker is proportional to the square root of the sample size. Studies with no
estimate presented did not meet the inclusion criteria for this infection and age group. Year
presented is the median year that baseline data were collected during the study.
(TIF)
S4 Fig. Gonorrhea prevalence among 25–49-year-olds, stratified by initial region and pop-
ulation type category. E Africa, Eastern Africa; SA, South Africa; S Africa, Southern Africa.
The area of the marker is proportional to the square root of the sample size. Studies with no
estimate presented did not meet the inclusion criteria for this infection and age group. Year
presented is the median year that baseline data were collected during the study.
(TIF)
S5 Fig. Syphilis overall prevalence among 15–24-year-olds, stratified by initial region and
population type category. E Africa, Eastern Africa; SA, South Africa; S Africa, Southern
Africa. The area of the marker is proportional to the square root of the sample size. Studies
with no estimate presented did not meet the inclusion criteria for this infection and age group.
Year presented is the median year that baseline data were collected during the study.
(TIF)
S6 Fig. Syphilis overall prevalence among 25–49-year-olds, stratified by initial region and
population type category. E Africa, Eastern Africa; SA, South Africa; S Africa, Southern
Africa. The area of the marker is proportional to the square root of the sample size. Studies
with no estimate presented did not meet the inclusion criteria for this infection and age group.
Year presented is the median year that baseline data were collected during the study.
(TIF)
S7 Fig. High-titer, active syphilis prevalence among 15–24-year-olds, stratified by initial
region and population type category. E Africa, Eastern Africa; SA, South Africa; S Africa,
Southern Africa. The area of the marker is proportional to the square root of the sample size.
Studies with no estimate presented did not meet the inclusion criteria for this infection and age
group. Year presented is the median year that baseline data were collected during the study.
(TIF)
S8 Fig. High-titer, active syphilis prevalence among 25–49-year-olds, stratified by initial
region and population type category. E Africa, Eastern Africa; SA, South Africa; S Africa,
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Southern Africa. The area of the marker is proportional to the square root of the sample size.
Studies with no estimate presented did not meet the inclusion criteria for this infection and
age group. Year presented is the median year that baseline data were collected during the
study.
(TIF)
S9 Fig. Syphilis overall prevalence among 15–24-year-olds among studies with titer infor-
mation. E Africa, Eastern Africa; SA, South Africa; S/E Africa, Southern and Eastern Africa.
The area of the marker is proportional to the square root of the sample size. Studies with no
estimate presented did not meet the inclusion criteria for this infection and age group. Year
presented is the median year that baseline data were collected during the study. Includes stud-
ies of HIV-discordant couples.
(TIF)
S10 Fig. Syphilis overall prevalence among 25–49-year-olds among studies with titer infor-
mation. E Africa, Eastern Africa; SA, South Africa; S/E Africa, Southern and Eastern Africa.
The area of the marker is proportional to the square root of the sample size. Studies with no
estimate presented did not meet the inclusion criteria for this infection and age group. Year
presented is the median year that baseline data were collected during the study. Includes stud-
ies of HIV-discordant couples.
(TIF)
S11 Fig. Syphilis overall prevalence among 15–24-year-olds among studies with titer infor-
mation, stratified by initial region and population type category. E Africa, Eastern Africa;
SA, South Africa; S Africa, Southern Africa. The area of the marker is proportional to the
square root of the sample size. Studies with no estimate presented did not meet the inclusion
criteria for this infection and age group. Year presented is the median year that baseline data
were collected during the study.
(TIF)
S12 Fig. Syphilis overall prevalence among 25–49-year-olds among studies with titer infor-
mation, stratified by initial region and population type category. E Africa, Eastern Africa;
SA, South Africa; S Africa, Southern Africa. The area of the marker is proportional to the
square root of the sample size. Studies with no estimate presented did not meet the inclusion
criteria for this infection and age group. Year presented is the median year that baseline data
were collected during the study.
(TIF)
S13 Fig. Trichomoniasis prevalence among 15–24-year-olds, stratified by initial region
and population type category. E Africa, Eastern Africa; SA, South Africa; S Africa, Southern
Africa. The area of the marker is proportional to the square root of the sample size. Studies
with no estimate presented did not meet the inclusion criteria for this infection and age group.
Year presented is the median year that baseline data were collected during the study.
(TIF)
S14 Fig. Trichomoniasis prevalence among 25–49-year-olds, stratified by initial region
and population type category. E Africa, Eastern Africa; SA, South Africa; S Africa, Southern
Africa. The area of the marker is proportional to the square root of the sample size. Studies
with no estimate presented did not meet the inclusion criteria for this infection and age group.
Year presented is the median year that baseline data were collected during the study.
(TIF)
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S15 Fig. HSV-2 prevalence among 15–24-year-olds, stratified by initial region and popula-
tion type category. E Africa, Eastern Africa; SA, South Africa; S Africa, Southern Africa. The
area of the marker is proportional to the square root of the sample size. Studies with no esti-
mate presented did not meet the inclusion criteria for this infection and age group. Year pre-
sented is the median year that baseline data were collected during the study.
(TIF)
S16 Fig. HSV-2 prevalence among 25–49-year-olds, stratified by initial region and popula-
tion type category. E Africa, Eastern Africa; SA, South Africa; S Africa, Southern Africa. The
area of the marker is proportional to the square root of the sample size. Studies with no esti-
mate presented did not meet the inclusion criteria for this infection and age group. Year pre-
sented is the median year that baseline data were collected during the study.
(TIF)
S17 Fig. Bacterial vaginosis prevalence among 15–24-year-olds, stratified by initial region
and population type category. E Africa, Eastern Africa; SA, South Africa; S Africa, Southern
Africa. The area of the marker is proportional to the square root of the sample size. Studies
with no estimate presented did not meet the inclusion criteria for this infection and age group.
Year presented is the median year that baseline data were collected during the study.
(TIF)
S18 Fig. Bacterial vaginosis prevalence among 25–49-year-olds, stratified by initial region
and population type category. E Africa, Eastern Africa; SA, South Africa; S Africa, Southern
Africa. The area of the marker is proportional to the square root of the sample size. Studies
with no estimate presented did not meet the inclusion criteria for this infection and age group.
Year presented is the median year that baseline data were collected during the study.
(TIF)
S1 Table. Inclusion and exclusion criteria for HC-HIV meta-analysis dataset.
(DOCX)
S2 Table. Studies considered for inclusion in the STI/BV IPD meta-analysis by STI/BV
and test technology used.
(DOCX)
S3 Table. Baseline characteristics by study population, all ages.
(DOCX)
S4 Table. Data availability of component datasets for the IPD meta-analysis.
(DOCX)
S1 Text. PRISMA checklist.
(DOCX)
S2 Text. IPD checklist.
(DOCX)
S3 Text. Protocol: Sexually transmitted infections among women in sub-Saharan Africa:
Individual participant data meta-analysis of prospective studies.
(DOCX)
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